Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions
Open Access
- 15 September 2018
- journal article
- research article
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 90 (9) , 92-100
Abstract
The urgency of the study is determined by the lack of data necessary in order to assess the safety of prolonged use of proton pump inhibitors (PPI) in patients with IHD combined with anti-aggregant therapy. The aim of the study was to study the relationship between the use of PPI and the risk of thrombotic complications in patients undergoing planned procedures of percutaneous coronary interventions (PCI) and receiving dual antiplatelet therapy. Materials and methods . The study is a prospective register of patients who successfully underwent planned percutaneous coronary intervention (PCI). The effect of PPI (omeprazole and pantoprazole) on the frequency of the combined end point cardiovascular death, ACS, AI, TIA, peripheral arterial thrombosis and PE was assessed using the Log-Rank criterion, as well as in a multivariate analysis (Cox proportional risk regression model). Results . A total of 391 patients were included in the study (23.1% women, mean age 61.2 [Symbol] 10.4 years). The median duration of follow-up was 18 months. During this period of time, 34 adverse events were recorded. Log-Rank analysis showed that the proportion of patients without adverse events in the omeprazole group was significantly lower in comparison with patients who did not receive PPI (0.56 vs. 0.84, Log-Rank p=0.003), and for pantoprazole no such pattern was found (0.89 against 0.84, Log-Rank p=0.21). The average level of residual platelet reactivity (ORT), as well as the number of patients with high ORT (> 208 PRU), did not differ significantly between the groups of omeprazole, pantoprazole and the group of patients not receiving PPI. According to multivariate analysis, omeprazole was an independent predictor of thrombotic complications after a planned PCI (OR 3.75, 95% confidence interval 1.72-8.17, p=-0.0009). Conclusion . Long-term use of omeprazole (at least 30 days) is an independent predictor of thrombotic complications in patients who underwent planned PCI. Keywords : proton pump inhibitors, omeprazole, pantoprazole, IHD, percutaneous coronary interventions, risk of cardiovascular complications.Keywords
This publication has 21 references indexed in Scilit:
- Effect of the Clopidogrel–Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
- A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy VolunteersJACC, 2012
- Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary InterventionCirculation: Cardiovascular Interventions, 2011
- Esomeprazole With Clopidogrel Reduces Peptic Ulcer Recurrence, Compared With Clopidogrel Alone, in Patients With AtherosclerosisGastroenterology, 2011
- Clopidogrel with or without omeprazole in coronary disease.New England Journal of Medicine, 2011
- Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial InfarctionCirculation, 2011
- Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysisCanadian Medical Association Journal, 2010
- Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 2010
- PROTON PUMP INHIBITORS ARE ASSOCIATED WITH CARDIOVASCULAR RISK INDEPENDENT OF CLOPIDOGREL USE IN PATIENTS WITH MYOCARDIAL INFARCTION: A NATIONWIDE PROPENSITY SCORE MATCHED STUDYJACC, 2010
- A population-based study of the drug interaction between proton pump inhibitors and clopidogrelCanadian Medical Association Journal, 2009